Entities / Company
Indivior.
specialty pharmaceuticals business headquartered in Richmond, Virginia
- Reports this week
- 4
- Active events
- 3
- Connections
- 36
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
Active this week
-
Indivior and Addex Therapeutics regained full global rights to GABAB PAM assets.Some support2 reports
-
Addex Therapeutics and Indivior are partnering on a drug candidate.Some support3 reports1 development inside
-
Indivior and NRx Pharmaceuticals are competing in the specialized pharmaceutical market.Some support1 report
Earlier this month
One to three months ago
-
MarketBeat reports on stock ratings for Indivior, concurrent with the disclosure of an insider sale in a legal filing with the SEC.Well supported6 reports
-
Indivior develops and sells drugs in the market.Some support1 report
-
Supernus shareholders are investigating a potential sale of the company to Indivior.Some support1 report
-
Indivior and Supernus Pharmaceuticals agreed to a tax-free merger of equals, and they are also seeking FDA approval for a second ONAPGO supplier.Some support3 reports
Gone quiet
No new reports in 90+ days-
Indivior's CFO disclosed a sale of company stock via an SEC filing on June 19, 2026.Some support1 report
-
Indivior, Addex Therapeutics, and Johnson & Johnson completed IND-enabling studies for substance use disorders and regained rights to the mGluR2 program.Speculative1 report
-
Indivior appointed Tony Kingsley to its Board of Directors, with David Wheadon serving as Chair.Speculative1 report
-
Indivior's inclusion in a Russell index aligns with its U.S. business profile.Speculative1 report
-
Indivior appointed Vanessa Procter as EVP, who previously worked at Alexion Pharmaceuticals, and confirmed its headquarters in Richmond.Speculative1 report
-
Indivior announced strategic corporate developments on July 28, 2025, including executive appointments, market strategy shifts, and FDA approval for updated labeling of SUBLOCADE.Some support1 report1 development inside
-
Indivior cancelled its secondary listing on the London Stock Exchange.Some support1 report
-
Indivior, headquartered in Richmond, VA, participated in investor events hosted by Morgan Stanley in New York City.Some support4 reports
No events began in the chosen period. Widen it, or reset.
Around Indivior this week
News at the entities that move Indivior most-
Addex Therapeutics OperationalAddex Therapeutics and Bayer Aktiengesellschaft are being compared as healthcare companies.Moves Indivior
-
London StructuralHelen Flanagan is leading a suspected state-threat investigation through Counter Terrorism Policing in London.Moves Indivior
-
MarketBeat Mentioned togetherApple Inc. stock is traded on Nasdaq, and Jefferies Financial Group restated a hold rating on the company.Moves Indivior
-
SEC StructuralDHS, DOJ, and SEC formed a joint initiative to establish a Trade Fraud Task Force, setting standards for compliance.Moves Indivior
-
Richmond Shared contextJim Ukrop founded and led Ukrop's Supermarkets in Richmond, which operated with an in-house bank before being sold to a larger institution.Moves Indivior
-
New York City Shared contextJoint entities are driving a high volume of General Obligation bond issuance in New York City.Moves Indivior
Connections
The 8 strongest of 36, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Addex Therapeutics Operational
Indivior and Addex Therapeutics are engaged in an ongoing operational partnership focused on the development of a GABAB PAM drug candidate.
-
Patrick Barry Structural
Patrick Barry serves as the Chief Commercial Officer for Indivior.
-
SEC Structural
Indivior is subject to regulatory oversight by the SEC, requiring the disclosure of corporate insider transactions.
-
London Structural
Indivior is undergoing a delisting process from the London Stock Exchange.
-
Richmond Shared context
Indivior is headquartered and conducts operations in Richmond, Virginia.
-
MarketBeat Mentioned together
MarketBeat, a financial information service, is currently providing coverage and reporting on Indivior's stock ratings.
-
New York City Shared context
Indivior conducts meetings and participates in events within New York City.
-
Nasdaq Mentioned together
No evidence was provided linking Indivior and Nasdaq.
History
Events by the month they beganSeptember 2026
3 eventsAugust 2026
3 eventsJuly 2026
1 eventShow 1 earlier month
June 2026
9 events- Addex Therapeutics and Indivior are partnering on a drug candidate.
- Indivior's CFO disclosed a sale of company stock via an SEC filing on June 19, 2026.
- Indivior, Addex Therapeutics, and Johnson & Johnson completed IND-enabling studies for substance use disorders and regained rights to the mGluR2 program.
- Indivior appointed Tony Kingsley to its Board of Directors, with David Wheadon serving as Chair.
- Indivior's inclusion in a Russell index aligns with its U.S. business profile.
- Indivior appointed Vanessa Procter as EVP, who previously worked at Alexion Pharmaceuticals, and confirmed its headquarters in Richmond.
- Indivior announced strategic corporate developments on July 28, 2025, including executive appointments, market strategy shifts, and FDA approval for updated labeling of SUBLOCADE.
- Indivior cancelled its secondary listing on the London Stock Exchange.
- Indivior, headquartered in Richmond, VA, participated in investor events hosted by Morgan Stanley in New York City.